HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.